OPRXNasdaqServices-Business Services, NECFiscal year ends December 31
OptimizeRx Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.74+0.24 (+2.82%)
Close on Oct 19, 2026
- Market cap
- $164.19M
- P/E (TTM)
- 36.4
- Dividend yield
- –
OptimizeRx Corp revenue by segment
By business segment
By product or service
| Revenue | Q3 23 | Q3 22 | % of revenue | YoY |
|---|---|---|---|---|
| Revenue recognized over time [Member] | $14.82M | $14.50M | 90.7% | +2.1% |
| Revenue recognized at a point in time [Member] | $1.52M | $581.56K | 9.3% | +160.7% |
By region
From the segment and revenue-disaggregation notes of OptimizeRx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.